ENZON PHARMACEUTICALS Files Administrative 8-K on Dec 31 Event
Ticker: ENZN · Form: 8-K · Filed: Jan 5, 2024 · CIK: 727510
Complexity: simple
Sentiment: neutral
Topics: administrative, corporate-governance, other-events
TL;DR
**ENZON PHARMACEUTICALS filed a routine 8-K, no major news.**
AI Summary
ENZON PHARMACEUTICALS, INC. filed an 8-K on January 5, 2024, reporting an 'Other Event' that occurred on December 31, 2023. The filing indicates the company is incorporated in Delaware, has its principal executive offices in Cranford, New Jersey, and operates under the SIC code 2836 (Biological Products). This filing is primarily administrative, updating basic company information, and does not disclose any new material financial or operational events that would directly impact a stock owner's investment decision.
Why It Matters
This filing is largely administrative, updating basic company information, and does not contain new material financial or operational news that would immediately affect the stock price or an investor's outlook.
Risk Assessment
Risk Level: low — The filing is administrative and does not disclose any events that introduce new financial or operational risks.
Analyst Insight
Given the administrative nature of this 8-K, a smart investor would recognize it contains no new material information and would not base any trading decisions solely on this filing. Further research into the company's financial performance and strategic initiatives would be necessary.
Key Numbers
- 2023-12-31 — Date of earliest event reported (The date the 'Other Event' occurred.)
- 2024-01-05 — Filed as of date (The date the 8-K was filed with the SEC.)
- 732-980-4500 — Registrant's telephone number (Contact number for ENZON PHARMACEUTICALS, INC.)
- 2836 — Standard Industrial Classification (SIC) (Industry code for Biological Products (No Diagnostic Substances).)
Key Players & Entities
- ENZON PHARMACEUTICALS, INC. (company) — the registrant filing the 8-K
- Delaware (company) — state of incorporation for ENZON PHARMACEUTICALS, INC.
- Cranford, New Jersey (company) — location of principal executive offices for ENZON PHARMACEUTICALS, INC.
- 0000727510 (company) — Central Index Key (CIK) for ENZON PHARMACEUTICALS, INC.
- 001-36435 (company) — Commission File Number for ENZON PHARMACEUTICALS, INC.
Forward-Looking Statements
- The stock price of ENZON PHARMACEUTICALS, INC. will remain unaffected by this specific 8-K filing. (ENZON PHARMACEUTICALS, INC.) — high confidence, target: 2024-01-08
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on December 31, 2023.
What is the primary business classification of ENZON PHARMACEUTICALS, INC. according to its SIC code?
ENZON PHARMACEUTICALS, INC. is classified under SIC code 2836, which corresponds to 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)'.
Where are the principal executive offices of ENZON PHARMACEUTICALS, INC. located?
The principal executive offices of ENZON PHARMACEUTICALS, INC. are located at 20 Commerce Drive (Suite 135), Cranford, New Jersey, 07016.
What is the Commission File Number for ENZON PHARMACEUTICALS, INC.?
The Commission File Number for ENZON PHARMACEUTICALS, INC. is 001-36435.
Does this 8-K filing indicate any securities registered pursuant to Section 12(b) of the Act?
No, the filing explicitly states 'None' for 'Title of Each Class' and 'N/A' for 'Trading Symbol(s)' and 'Name of Each Exchange on Which Registered' under 'Securities registered pursuant to Section 12(b) of the Act'.
Filing Stats: 443 words · 2 min read · ~1 pages · Grade level 12.3 · Accepted 2024-01-05 16:05:44
Key Financial Figures
- $1,274,400 — erred Stock") in an aggregate amount of $1,274,400, or $31.86 per share of Series C Prefer
- $31.86 — n an aggregate amount of $1,274,400, or $31.86 per share of Series C Preferred Stock.
Filing Documents
- tm241484d1_8k.htm (8-K) — 22KB
- 0001104659-24-001789.txt ( ) — 183KB
- enzn-20231231.xsd (EX-101.SCH) — 3KB
- enzn-20231231_lab.xml (EX-101.LAB) — 33KB
- enzn-20231231_pre.xml (EX-101.PRE) — 22KB
- tm241484d1_8k_htm.xml (XML) — 3KB
01 Other
Item 8.01 Other Events The Board of Directors of Enzon Pharmaceuticals, Inc. (the "Company"), with respect to the fiscal year ended December 31, 2023, declared the payment of the 3% cash dividend to the holders of its 40,000 outstanding shares of Series C Non-Convertible Redeemable Preferred Stock (the "Series C Preferred Stock") in an aggregate amount of $1,274,400, or $31.86 per share of Series C Preferred Stock. The dividends will be paid on January 17, 2024, to the holders of record of the Company's Series C Preferred Stock as of January 10, 2024.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENZON PHARMACEUTICALS, INC. (Registrant) Date: January 5, 2024 By: /s/ Richard L. Feinstein Name: Richard L. Feinstein Title: Chief Executive Officer, Chief Financial Officer and Secretary